DK3783000T3 - Makrocyklisk kinasehæmmer - Google Patents
Makrocyklisk kinasehæmmer Download PDFInfo
- Publication number
- DK3783000T3 DK3783000T3 DK19788896.9T DK19788896T DK3783000T3 DK 3783000 T3 DK3783000 T3 DK 3783000T3 DK 19788896 T DK19788896 T DK 19788896T DK 3783000 T3 DK3783000 T3 DK 3783000T3
- Authority
- DK
- Denmark
- Prior art keywords
- kinase inhibitor
- macrocyclic kinase
- macrocyclic
- inhibitor
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810341398 | 2018-04-18 | ||
| PCT/CN2019/083086 WO2019201282A1 (zh) | 2018-04-18 | 2019-04-17 | 一种大环类激酶抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3783000T3 true DK3783000T3 (da) | 2022-08-01 |
Family
ID=68239243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19788896.9T DK3783000T3 (da) | 2018-04-18 | 2019-04-17 | Makrocyklisk kinasehæmmer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11584759B2 (da) |
| EP (1) | EP3783000B1 (da) |
| JP (1) | JP7094438B2 (da) |
| KR (1) | KR102621272B1 (da) |
| CN (1) | CN110386945B (da) |
| AU (1) | AU2019254979B2 (da) |
| CA (1) | CA3099493C (da) |
| DK (1) | DK3783000T3 (da) |
| ES (1) | ES2925578T3 (da) |
| WO (1) | WO2019201282A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| PT3658148T (pt) | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Compostos macrocíclicos e utilizações dos mesmos |
| MX2020006490A (es) | 2017-12-19 | 2020-08-17 | Turning Point Therapeutics Inc | Compuestos macrociclicos para tratar enfermedades. |
| CN111171020A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| CN113004305B (zh) * | 2019-12-19 | 2024-04-09 | 赛诺哈勃药业（成都）有限公司 | 大环化合物及其制备方法和用途 |
| CN111875620B (zh) * | 2020-09-28 | 2020-12-11 | 上海美迪西生物医药股份有限公司 | 吡唑并嘧啶类大环衍生物及其应用 |
| CN113355651A (zh) * | 2021-05-19 | 2021-09-07 | 湖北省黄麦岭磷化工有限责任公司 | 无水氟化铝的气相制备方法 |
| CN113754657B (zh) * | 2021-09-22 | 2023-01-17 | 广州白云山医药集团股份有限公司白云山制药总厂 | 大环类化合物的晶型及其制备方法和应用 |
| WO2023205701A1 (en) * | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| AU2023255692A1 (en) | 2022-04-20 | 2024-10-03 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005045124A (ja) * | 2003-07-24 | 2005-02-17 | Sony Corp | ステンシルマスク、荷電粒子照射装置及び方法 |
| CN100506823C (zh) | 2003-12-18 | 2009-07-01 | 詹森药业有限公司 | 作为抗增殖药剂的吡啶并嘧啶和嘧啶并嘧啶衍生物 |
| CA2549869C (en) * | 2003-12-18 | 2015-05-05 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents |
| WO2010085597A1 (en) * | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| WO2012125668A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| CN102757448B (zh) | 2011-04-26 | 2016-04-06 | 中南大学 | 大环类激酶抑制剂化合物、制备方法及其作为药物的应用 |
| US9861635B2 (en) | 2013-05-06 | 2018-01-09 | Merck Patent Gmbh | Macrocycles as kinase inhibitors |
| MX2017017097A (es) * | 2015-07-02 | 2018-05-23 | Tp Therapeutics Inc | Macrociclos diarílicos quirales como moduladores de proteínas quinasas. |
| CN111171020A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
-
2019
- 2019-04-17 AU AU2019254979A patent/AU2019254979B2/en active Active
- 2019-04-17 DK DK19788896.9T patent/DK3783000T3/da active
- 2019-04-17 ES ES19788896T patent/ES2925578T3/es active Active
- 2019-04-17 WO PCT/CN2019/083086 patent/WO2019201282A1/zh unknown
- 2019-04-17 US US17/048,604 patent/US11584759B2/en active Active
- 2019-04-17 JP JP2021506030A patent/JP7094438B2/ja active Active
- 2019-04-17 EP EP19788896.9A patent/EP3783000B1/en active Active
- 2019-04-17 KR KR1020207033016A patent/KR102621272B1/ko active IP Right Grant
- 2019-04-17 CN CN201910309761.8A patent/CN110386945B/zh active Active
- 2019-04-17 CA CA3099493A patent/CA3099493C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7094438B2 (ja) | 2022-07-01 |
| US11584759B2 (en) | 2023-02-21 |
| CN110386945B (zh) | 2021-09-28 |
| EP3783000A1 (en) | 2021-02-24 |
| KR102621272B1 (ko) | 2024-01-05 |
| JP2021517914A (ja) | 2021-07-29 |
| EP3783000B1 (en) | 2022-07-06 |
| WO2019201282A1 (zh) | 2019-10-24 |
| ES2925578T3 (es) | 2022-10-18 |
| KR20210018223A (ko) | 2021-02-17 |
| AU2019254979B2 (en) | 2021-08-12 |
| EP3783000A4 (en) | 2021-04-21 |
| CA3099493C (en) | 2023-08-22 |
| CN110386945A (zh) | 2019-10-29 |
| AU2019254979A1 (en) | 2020-11-26 |
| CA3099493A1 (en) | 2019-10-24 |
| US20210147443A1 (en) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54543A (fr) | Inhibiteurs de kif18a | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| DK3783000T3 (da) | Makrocyklisk kinasehæmmer | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| DK3796975T3 (da) | Sulfonylaminobenzamidderivater | |
| MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
| DK3763625T3 (da) | Random kasselukker | |
| MA44607A (fr) | Inhibiteurs de kinase | |
| DK3710457T3 (da) | Immunproteasomhæmmere | |
| DK3877364T3 (da) | Rock-kinasehæmmere | |
| DK3626317T3 (da) | Mål | |
| DK3770162T3 (da) | Dihydrochromenderivater | |
| DK3752258T3 (da) | Trampolin | |
| DK3720840T3 (da) | Cathepsinhæmmere | |
| UA39651S (uk) | Стусло | |
| DK3587968T3 (da) | Fluidsystem | |
| MA49925A (fr) | Claie | |
| ES1217228Y (es) | Cajón descontaminador | |
| EA202190617A3 (ru) | Соединения-ингибиторы бета-лактамаз | |
| DE112019000442A5 (de) | Ringtilgereinrichtung |